Matching of Patients
Each patient who underwent radiosurgery was matched to two patients from a pool of over 500 who underwent surgery for brain metastasis over a similar time period. The large number of surgically treated patients allowed us to select 62 well-matched patients, thereby increasing the statistical power of the study. Patients were matched according to the following criteria: histological characteristics of the primary tumor, extent of systemic disease, preoperative KPS score, time to brain metastasis, number of brain metastases, and patient age and sex. All of these are known or potential prognostic indicators. 20 The characteristics of both patient groups and the results of a statistical comparison are presented in Table 1 .
Location of Tumor
The hypothetical surgical morbidity of resection of the lesions in the radiosurgery group was similar to that of the surgery group. Retrospective analysis of the tumors treated with radiosurgery demonstrated that 80.5% were surgically resectable with minimal or no morbidity.
Whole-Brain Radiation Therapy
Treatment with whole-brain radiation therapy (WBRT) was similar in both groups of patients. Of the 22 patients in the radiosurgery group receiving WBRT, 16 received preradiosurgery WBRT and six received periradiosurgery WBRT. None of the radiosurgically treated patients had WBRT withheld until recurrence. Two patients in the surgically treated group had WBRT at the time of recurrence. This difference was not statistically significant (p Ͼ 0.05).
Cause-of-Death Analysis
Cause of death was defined as "neurological" in patients who died with stable systemic disease and advancing brain metastasis or radiation effect; as "systemic" in patients who died with stable brain metastasis and advancing systemic disease; and as "combined" in patients who died with progressive neurological and systemic disease. Systemic and neurological survival periods were calculated using the Kaplan-Meier 12 survival method. In calculating systemic survival periods, patient deaths from systemic or combined causes were used as the endpoints, whereas all other patients were censored at last follow-up examination or at time of death. In calculating neurological survival periods, patient deaths from neurological or combined causes were used as the end points, whereas all other patients were censored at last follow-up examination or at time of death.
Recurrence of Tumor
"Local recurrence" was defined as failure of the treatment to control the treated lesion as exhibited on follow-up magnetic resonance (MR) imaging. Growth of a radiosurgically treated lesion that was greater than 25% or radiographic recurrence of a surgically treated lesion was labeled a local recurrence. We prefer to use the term "progression of disease" for the radiosurgery group because radiographic growth of a lesion does not distinguish between tumor growth, radiation necrosis, or tumor hemorrhage. "Distant recurrence" was defined as development of a new brain metastasis elsewhere in the brain. Reoperation was considered for patients in both groups who developed recurrence in the brain and had limited systemic disease.
Statistical Analysis
Survival curves were drawn using the Kaplan-Meier product-limit method. 12 The log-rank test and univariate Cox proportional hazards regression analyses were applied to evaluate the differences between survival curves. 7 The Cox regression model was used to study the effects of multiple covariates on patient survival periods. 7 The following covariates were used in the Cox regression model: surgical or radiosurgical treatment, site of the primary tumor, extent of systemic disease, preoperative KPS score, patient age, presence of multiple lesions, use of WBRT, and use of chemotherapy. Where indicated, 95% confidence intervals (CIs) and relative risks (RRs) are given. period in the surgical group was 16.4 months, whereas that in the radiosurgical group was 7.5 months. The 1-year survival rates for the surgical and radiosurgical groups were 58% (95% CI 44%-71%) and 27% (95% CI 11%-50%), respectively. This difference was statistically significant according to both univariate (p = 0.0041, RR = 2.36) and multivariate (p = 0.0009, RR = 3.17) analyses.
Results

Survival Analysis
Cause-of-Death Analysis
Causes of death are shown in Table 2 . Causes of death differed significantly between the two groups (p = 0.037, Pearson Chi-square test). Neurological causes accounted for 50% of deaths in the radiosurgical group but only 19% of deaths in the surgical group. Figure 2 left displays a comparison of systemic survival periods in the surgical and radiosurgical groups. The median systemic survival period in the surgical group was 25 months; the median was not reached in the radiosurgical group. The rates of 6-month freedom from systemic death were 84% for the surgical group (95% CI 72%-92%) and 79% for the radiosurgical group (95% CI 55%-94%). There was no statistically significant difference in systemic survival periods (p = 0.28, RR = 1.53) between the two groups. Figure 2 right shows a comparison of neurological survival periods in the surgical and radiosurgical groups. The median neurological survival for the surgical group was not reached; this period was 9 months in the radiosurgical group. The rates of 6-month freedom from neurological death were 95% for the surgical group (95% CI 86%-99%) and 79% for the radiosurgical group (95% CI 56%-94%). The 1-year freedom from neurological death was 83% for the surgical group (95% CI 67%-93%) and 40% for the radiosurgical group (95% CI 16%-68%). Radiosurgically treated patients had significantly shorter neurological survival periods according to both univariate (p Ͻ 0.0001, RR = 5.12) and multivariate (p = 0.05) analyses.
Recurrence of Tumor
In the surgical group, five patients (8.1%) suffered a local recurrence, 13 (21.0%) a distant recurrence, and three (4.8%) both local and distant recurrences. In the radiosurgical group, 12 patients (38.7%) suffered a local progression of disease, three (9.7%) a distant recurrence, and none (0%) both local and distant recurrences. The median time from the last MR image to death or last follow-up examination was 2 months each. plays a comparison of freedom from distant recurrence in the brain in the surgical and radiosurgical groups. The rate of 6-month freedom from distant recurrence was 86% for both the surgical (95% CI 73%-94%) and radiosurgical (95% CI 46%-99%) patients. The rates of 1-year freedom from distant recurrence were 75% for the surgical (95% CI 57%-88%) and 69% for the radiosurgical (95% CI 10%-99%) patients. There was no statistically significant difference in the distant recurrence rates between the two groups (p = 0.85, RR = 1.11). Figure 3 right shows a comparison of local control rates in the surgical and radiosurgical groups. Control of the treated lesion was significantly poorer in the radiosurgical group according to both univariate (p = 0.0001, RR = 5.00) and multivariate (p = 0.05) analyses.
Posttreatment Complications
Complications in the radiosurgery group included symptomatic radiation necrosis in four patients (12.9%). Spontaneous intratumoral hemorrhage occurred in three patients (9.7%), resulting in the death of one. Two of these patients had melanoma and one had lung adenocarcinoma. Three patients underwent craniotomy for tumor resection after radiosurgery failed to control the lesion size; one of these patients had significant radiation necrosis in addition to local tumor recurrence, the second had recurrent tumor, and the third had significant spontaneous intratumoral hemorrhage. Four patients developed significant deepvein thrombosis within 30 days after radiation treatment and required anticoagulation therapy or placement of a Greenfield filter. Radiosurgery patients generally remained in the hospital overnight and left the next day.
Complications in the surgery group included postoperative hematoma in two patients (one case of melanoma and one of unknown primary adenocarcinoma), neither requiring additional surgery. One patient had a postoperative wound infection that was treated with antibiotic medication. The median hospital stay for the surgical group was 4 days (range 2-22 days). This length of stay was significantly longer than the 1-day stay for radiosurgery patients (p Ͻ 0.0001, Wilcoxon sign-rank task).
Discussion
Patients with surgically resected brain metastasis survived significantly longer than similar patients treated with radiosurgery. Patients with cancer that has metastasized to the brain usually die from systemic disease or from brain metastasis. Neurological death occurs from increasing size or mass effect of the presenting brain metastasis or from new brain lesions. Kaplan-Meier analysis 12 demonstrates similar rates of mortality from systemic disease in the two groups; hence, systemic disease was equally advanced in both groups. In addition, the two groups had equivalent rates of distant recurrence. Thus the development of new brain metastasis was not the cause of the higher mortality rate in the radiosurgery group. This is to be expected, because neither surgery nor radiosurgery should have an impact on the development of new brain lesions. Additionally, WBRT, which can impact on the development of new brain metastasis, was given equally to both groups (Table 1) . However, analysis clearly demonstrated that in the radiosurgery group there was significantly poorer control of the treated lesions and this was the cause of the shorter overall survival periods in this group.
Patient Characteristics
The radiosurgery patients in our study are very comparable to patients in other selected reports in the literature (Table 3 ). The median size of the treated lesions in our study was 1.96 cm 3 and the median radiation doses at the isocenter and tumor margins were 20 Gy and 18.7 Gy, respectively, all of which are very similar to those in other studies. 1, 5, [7] [8] [9] 11, 12, 14, 16, 18, 19, 24 The 7.5-month median survival period is also quite comparable to those of other studies (Table 4) . Primary oncology care for our patients was
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Surgery vs. radiosurgery for brain metastasis 751   FIG. 3 . Graphs displaying comparisons between the surgical and radiosurgical groups for freedom from both distant (left) and local (right) recurrence of disease. There was no difference in distant recurrence rates between the two groups. Radiosurgery yielded significantly poorer local tumor control than surgery according to both univariate and multivariate analyses. n = number of patients. delivered at our institution, assuring the completeness of our follow-up study.
The surgery group in this paper is similar to those specified in published series from our own and other institutions (Table 4) . [2] [3] [4] [5] 9, 17, 18, 21, 23, 27 The recurrence and complication rates for this group were also similar to those reported in the literature. The median survival period in our surgical series is slightly longer than that of other published series due to the lower rate of systemic disease and higher KPS scores.
Recurrence of Tumor
Overall, 38.7% of the patients in the radiosurgery group had radiographic progression of disease. In this study, radiographic progression of disease includes tumor recurrence, radiation necrosis, and tumor hemorrhage. Recent literature has demonstrated that local tumor recurrence in surgical series occurs a median of 2.5 to 2.8 months prior to death for patients who do not undergo reoperation. 2, 3 Hence, to assess local recurrence accurately, the time from the last MR image to death should be as short as possible. In this study, the median time from the last MR image to death was 2 months.
Recent studies have reported that tumor recurrence occurs in 30% to 40% of all patients undergoing surgery. Local recurrence occurs in 5% to 15% of patients, distant recurrence occurs in 10% to 20%, and both local and distant recurrence in 5% to 10% of patients. 2, 18, 20, 24 The recurrence results in this surgical series are similar to results found in the literature.
Study Limitations
We retrospectively matched, by known prognostic indicators, radiosurgically treated patients to similar patients who were surgically treated. Features that were not matched included lesion location and size. The radiosurgery group generally had smaller lesions than the surgery group; however, a volumetric analysis of lesion size was not performed for the surgery group. The great majority (80.5%) of radiosurgical lesions were in surgically accessible areas of the brain. This is well illustrated by the fact that three patients underwent craniotomy after radiosurgery failed to control the lesion. Lesion location may have a small impact on survival, but this impact is possible only if the lesion is not locally controlled. The differences in lesion location and size were unlikely to result in a difference in survival length as great as that seen in this study (7.5 months vs. 16.4 months). Perhaps most importantly, lesion location should have had no impact on local control rates, which were also significantly different.
Finally, this study was retrospective, not prospective and randomized in nature. However, a randomized trial could not match the patients for all known factors unless large numbers of patients were recruited into each arm of the study. Even so, we have taken special care to ensure that both patient groups were well matched by a variety of indicators.
Management Guidelines
Radiosurgery is a new method of treatment that has certain advantages over surgery. Radiosurgery is noninvasive, requires a shorter hospital stay, and is somewhat less expensive than surgery. However, these advantages must be weighed against radiosurgery's potentially higher complication rate and shorter survival period compared with surgery. Additionally, surgery offers the advantage of providing histological verification. It is well established that 5% to 11% of patients with known systemic disease and a brain lesion consistent with brain metastasis actually have nonmetastatic disease. 18, 26 Thus, although radiosurgery remains a powerful treatment option for brain metastasis, it should be used primarily as an adjunct to surgery. Radiosurgery is indicated for lesions in surgically inaccessible locations; however, the definition of surgically inaccessible is often a matter of opinion. Modern neurosurgical techniques, including stereotaxy and intraoperative ultrasonography, have made many previously inaccessible lesions accessible. 19 Recent advances in cortical mapping have also aided in aggressive complication-free resection. Not only is lesion location important in determining accessibility, but size is also a consideration. For example, a deep white-matter lesion may be considered inaccessible if very small but accessible if larger. Thus, when faced with a small white-matter lesion in an eloquent region of brain and moderately advanced systemic disease, one may opt for radiosurgery.
Radiosurgery can be used as part of a multimodality treatment for patients with multiple brain metastases. We previously showed that resection of all brain metastases markedly prolongs survival of patients with multiple brain metastases. 2 In a patient with a large, symptomatic lesion and a small, deep white-matter lesion, the large lesion may be treated with surgery and the small one with radiosurgery.
Because radiosurgery is a noninvasive treatment, it may also have a role in treating patients who are not surgical candidates because of advanced systemic disease or poor medical condition. Radiosurgery is more effective at local tumor control than WBRT and, therefore, may be used as an adjunct to, or even in lieu of, WBRT for patients in poor medical condition. Thus, radiosurgery remains an important and powerful tool in the treatment of brain metastasis.
Conclusions
On the basis of our data, we conclude that surgery has produced better results than radiosurgery in the treatment of brain metastasis. Patients who undergo surgical treatment survive longer and have better local tumor control. Our data lead us to suggest that the indications for radiosurgery should be limited to surgically inaccessible metastatic tumors or patients in poor medical condition. Surgery should remain the treatment of choice whenever possible.
